Quest distributes Abbott bladder cancer probe:
This article was originally published in Clinica
Quest Diagnostics has agreed to distribute Abbott Laboratories' bladder cancer probe, Vysis UroVision DNA probe assay, in the US. New labelling claims on the product's effectiveness in monitoring bladder cancer recurrence were cleared by the FDA in March 2002. Vysis UroVision is based on fluorescence in situ hybridisation (FISH) technology, with which cancer cells can be examined while physically intact and are this not destroyed. Quest has been distributing Abbott's FISH-based breast cancer-diagnostic, PathyVision Her-2, since December 2001.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.